CRNX241220P37000
- 0.95
- 0.000.00%
Crinetics Newsroom
Crinetics Pharmaceuticals Strengthens Leadership With New Appointment
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Express News | Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Press Release: Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $87
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)
Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan
Express News | Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
Crinetics Announces FDA Acceptance of NDA for Paltusotine
Express News | Crinetics Pharmaceuticals Inc - FDA Targets Pdufa Date Sept 25, 2025 for Nda Review Completion
Express News | Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients With Acromegaly
Cushing Syndrome Pipeline Insight 2024, Featuring Key Players Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals and Key Products Relacorilant, SPI 62 and CRN-04894
Crinetics Price Target Raised to $87 From $80 at JMP Securities
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences